Meeting
2018 Genitourinary Cancers Symposium
PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).
Authors
Maha Hussain
Northwestern University, Chicago, IL
Maha Hussain , Karim Fizazi , Fred Saad , Per Rathenborg , Neal D. Shore , Eren Demirhan , Katharina Modelska , De Phung , Andrew Krivoshik , Cora N. Sternberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT02003924
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 3)
DOI
10.1200/JCO.2018.36.6_suppl.3
Abstract #
3
Poster Bd #
A4
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).
First Author: Maha H. A. Hussain
Poster
2020 ASCO Virtual Scientific Program
Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.
First Author: Shan Jiang
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.
First Author: Ugo De Giorgi
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
First Author: Naoki Fujita